The bill would shield pesticide manufacturers like Bayer from lawsuits claiming the company failed to warn consumers of ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

With billions in revenue at stake, the pharma giant has a 27-country parallel litigation effort to protect its blockbuster ...

While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...

BEIJING - US pharmaceutical giant Pfizer's new research and development (R&D) center officially opened at BioPark in the ...

BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...

Bayer (BAYZF) stock in focus as the company inks a licensing deal with Puhe BioPharma to develop a cancer candidate targeting ...

Bayer said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with ...